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Background: There have been few published reports on severe Plasmodium falciparum and Plasmodium vivax
malaria among adults in Africa.
Methods: Clinical pattern/manifestations of severe P. falciparum and P. vivax (according to World Health
Organization 2000 criteria) were described in adult patients admitted to Kassala Hospital, eastern Sudan.
Results: A total of 139 adult patients (80 males, 57.6%) with a mean (SD) age of 37.2 (1.5) years presented with
severe P. falciparum (113, 81.3%) or P. vivax (26, 18.7%) malaria. Manifestations among the 139 patients included
hypotension (38, 27.3%), cerebral malaria (23, 16.5%), repeated convulsions (18, 13.0%), hypoglycaemia (15, 10.8%),
hyperparasitaemia (14, 10.1%), jaundice (14, 10.1%), severe anaemia (10, 7.2%), bleeding (six, 4.3%), renal impairment
(one, 0.7%) and more than one criteria (27, 19.4%). While the geometric mean of the parasite count was
significantly higher in patients with severe P. vivax than with severe P. falciparum malaria (5,934.2 vs 13,906.6 asexual
stage parasitaemia per μL, p = 0.013), the different disease manifestations were not significantly different between
patients with P. falciparum or P. vivax malaria. Three patients (2.2%) died due to severe P. falciparum malaria. One
had cerebral malaria, the second had renal impairment, jaundice and hypoglycaemia, and the third had repeated
convulsions and hypotension.
Conclusions: Severe malaria due to P. falciparum and P. vivax malaria is an existing entity among adults in eastern
Sudan. Patients with severe P. falciparum and P. vivax develop similar disease manifestations.
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Malaria is a big health problem and is endemic in an
area where around two billion people live. Plasmodium
falciparum causes approximately 600,000 deaths each
year and the vast majority of the burden of malaria
mortality is in sub-Saharan African countries [1]. The
high mortality rate from P. falciparum is due to its
ability to induce severe malaria, and in some cases,
multiple organ dysfunction [2]. The presenting symptoms
and mortality patterns of severe malaria vary widely
according to the geographical setting and therefore
transmission intensity. In areas with high, stable* Correspondence: ishagadam@hotmail.com
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reproduction in any medium, provided the ortransmission in sub-Saharan Africa, severe anaemia in
infants, which has a relatively good prognosis, is the
main presentation, and severe malaria does not occur in
adults with acquired immunity [2]. In areas with moderate
transmission, cerebral malaria in young children is the most
common presentation. In areas with low transmission,
such as Southeast Asia, severe malaria occurs in all age
groups including adults. Cerebral malaria, renal failure,
severe jaundice, and pulmonary oedema are the main
manifestations in the young adult population [2]. Yet the
determinants of severe malaria and its pathophysiology
are not completely understood. Therefore, epidemiological
studies of severe malaria and its related deaths may
provide additional understanding of its disease course,
and, eventually, lead to improved case management.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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among children in Africa, there are few published studies
regarding severe malaria among adult African patients
[3-5]. Furthermore, these studies had a greater emphasis
on P. falciparum malaria and there have been no
published data on severe Plasmodium vivax infection
among African adults. Until recently, P. vivax was
considered a benign parasite compared with P. falciparum.
The current study was conducted at Kassala Hospital
in eastern Sudan to investigate the manifestations and
epidemiology of severe P. falciparum and P. vivax
malaria among adult patients, so as to add to the previous
studies on severe malaria in Sudan [6-8]. Such data are of
paramount importance for care-givers, health planners
and researchers. The geographical area is characterized by
unstable malaria transmission, and P. falciparum (95%)
was the main species in the area. In contrast, P. vivax
was considered rare and constitutes only 3% of the
Plasmodium species in the area [9]. There is recent
evidence that the rate of P. vivax malaria is increasing in
this setting [10].
Methods
A descriptive hospital-based study was conducted at
Kassala Hospital, eastern Sudan, during two transmission
seasons (between August and December, 2011 and 2012)
to investigate the presentation/manifestation of severe
malaria caused by P. falciparum or P. vivax (Figure 1).
All patients, or their relatives in the case of comatose
patients, provided informed consent, and their socio-
demographic and clinical data (temperature, weight
and fever history) were collected using standard
questionnaires. Patients with one or more manifestations
of severe P. falciparum or P. vivax malaria according to
World Health Organization (WHO) criteria were enrolled
[2]. Pregnant women were not included. These criteria
included cerebral malaria (unarousable coma and assessed
by Glasgow coma scale), convulsions (more than two
per 24 hours), hypotension (systolic blood pressure <70
mmHg with cold extremities), severe anaemia (haemo-
globin <7 gm/dl), jaundice (detected clinically or bilirubin
levels >3 mg/dl), hypoglycaemia (blood glucose <40 mg/dl)
and hyperparasitaemia (parasite count >100,000 asexual
stage parasitaemia/μl) as described by WHO guidelines,
and the rest were considered as uncomplicated cases [2].
Thick and thin blood films were prepared from capillary
blood, stained with Giemsa, and 100 oil immersion fields
were examined. The parasite density was evaluated by
counting the number of asexual parasites for every
200 leukocytes, assuming a leukocyte count of 8,000
leukocytes/μl. All slides were double checked in a
blinded manner and only considered negative if no
parasites were detected in 100 oil immersion fields. If
gametocytes were seen, then the count was extendedto 500 oil immersion fields. Haemoglobin concentrations
were estimated using a HemoCue haemoglobinometer
(HemoCue AB, Angelhom, Sweden). Blood glucose was
measured at baseline before quinine infusion and two
hours after quinine infusion if there was clinical suspicion
of hypoglycaemia using the bedside device Accu-Chek™
Multiclix (Roche Diagnostics, Mannheim Germany). The
Accu-Chek™ machine was calibrated weekly and a new
box of test strips was opened each time.
Resuscitation and supportive management were given
according to WHO guidelines [11] including correction
of hypoglycaemia with 10% glucose, termination of
convulsions with intravenous diazepam if they persisted
for more than three minutes. Paracetamol was given
every six hours until defervescence. Those with severe
anaemia (haemoglobin <7 g/dl) and respiratory distress
were transfused with blood screened for hepatitis and
HIV. Vital signs were measured every 15 minutes for the
first hour, then every two hours until 24 hours, and
thereafter every six hours until patients were discharged
from the hospital. Baseline investigations were performed
for every patient upon admission and repeated when
clinically indicated. These included measuring levels
of haemoglobin, serum urea, serum creatinine, serum
bilirubin and white blood cell counts.
Treatment during the first malaria season of 2011
consisted of quinine (quinine dihydrochloride, 20 mg
salt/kg of loading dose, followed by 10 mg/kg three
times a day over two to three hours, that was changed to
oral quinine tablet when the patient could tolerate
them). During the second season, intravenous artesunate
was used with quinine in an open clinical trial. Artesunate
was given as 2.4 mg/kg body weight at 0, 12, and 24 h,
and then daily. Each 60mg vial of artesunic acid (Guilin,
Pharmaceutical Factory, Guangxi, People’s Republic of
China) was dissolved in 1mL of 5% sodium bicarbonate to
form sodium artesunate and then mixed with 5mL of 5%
dextrose. Details of the response to treatment will be
described in a future report.Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL, USA) version 16.0) and double
checked before analysis. Data were checked for normality,
and the Student t-test and analysis of variance were used
for normally distributed data to compare between two or
more than two groups, respectively. Proportions were
compared by χ2-test. P-values <0.05 were considered
significant.Ethical statement
The study received ethical approval from the Research
Board at the Ministry of Health Kassala, Sudan.
Figure 1 Map of Sudan.
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Of the total 9,559 adult patients presented to the hospital
during the study period, 2,124 (22.0%) patients had
malaria. Among 2,124 patients with malaria, 1,985
patients had uncomplicated malaria, 139 patients (80
males, 57.6%) with a mean (SD) age of 37.2 (1.5) years
presented with severe P. falciparum (113, 81.3%) or P.
vivax (26, 18.7%) malaria (Figure 2). The ratio of severe P.
falciparum to severe P. vivax malaria was 4.3 : 1.0. There
were no cases of P. falciparum and P. vivax co-infection.
There was no significant difference between the manifes-
tations/presentations in patients enrolled in the 2011
season (55, 40%) and those in the 2012 season (84, 60.0%).
Among 139 patients with either P. falciparum or P.
vivax infection, the frequency of symptoms were as
follows: hypotension (38, 27.3%), cerebral malaria (23,
16.5%), repeated convulsions (18, 13.0%), hypoglycaemia
(15, 10.8%), jaundice (14, 10.1%), hyperparasitaemia (14,
10.1%), severe anaemia (10, 7.2%), bleeding (six, 4.3%),renal impairment (one, 0.7%) and more than one criteria
(27, 19.4%) (Figures 2 and 3). None of the patients had
respiratory distress syndrome. The different manifestations
of severe malaria were not significantly different between
those infected with P. falciparum or P. vivax malaria
(Table 1). The geometric mean of the parasite count
was significantly higher in patients with severe P. vivax
than in patients with severe P. falciparum malaria
(5,934.2 vs 13,906.6; P = 0.013, Table 1).
Three patients presented with three manifestations of
severe malaria as follows: patient 1: cerebral malaria,
bleeding (epistaxis) and hypoglycaemia; patient 2: cerebral
malaria with repeated convulsions and hypotension; and,
patient 3: hypotension, severe anaemia and jaundice. Five
patients developed severe anaemia and jaundice. There
may be an overlap between the three main manifestations
(hypotension, convulsion and cerebral malaria) of severe
malaria. While there was no significant difference in levels
of blood glucose, white blood cells and parasite counts
Figure 2 Clinical categorization of patients presenting with malaria-like symptoms.
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sion and cerebral malaria, their age (patients with cerebral
malaria were older than those with convulsions, or
hypotension) and haemoglobin were significantly higher
in patients with cerebral malaria (Table 2).Figure 3 Presentations of severe Plasmodium falciparum and
Plasmodium vivax malaria.Three patients (2.2%) died due to severe P. falciparum
malaria. One had cerebral malaria, the second had renal
impairment, jaundice and hypoglycaemia, and the third
had repeated convulsions and hypotension.
Discussion
The current study demonstrated a high ratio of P.
falciparum to P. vivax malaria (4.3 : 1.0) in patients from
eastern Sudan. In addition, the predominant manifestations
of severe malaria were hypotension (27.3%), cerebral
malaria (16.5%), and convulsions (13.0%), and their
frequency was not significantly different between patients
with P. falciparum or P. vivax malaria. It has been
demonstrated that severe malarial anaemia was the most
common complication (45.4%) of P. falciparum malarial
infection among patients in a hospital (Gedarif ) in eastern
Sudan [8]. The difference in dominant complications
observed between the two studies may be attributable to
the age difference, which ranged between two and four
years in the Gedarif study compared with a range of
17–78 years, in the current study [8]. Anaemia was
the most common manifestation (30%), followed by
hypoglycaemia, of severe malaria among pregnant women
in the same study area [6]. Both clinical manifestations
(anaemia and hypoglycaemia) were less prominent in the
current study, perhaps because pregnant patients were
Table 1 The mean (SD) [range] of the clinical and biochemical data of patients with severe Plasmodium falciparum and
Plasmodium vivax malaria
Variable P. falciparum P. vivax P-value
(Number = 113) (Number = 26)
Age, years 38.0 (15.5) 34.2 (12.6) 0.260
[18.0–78.0] [17.0–70.0]
Weight, kg 67.8 (13.4) 70.3 (11.0) 0.374
[39.0–123.0] [39.0–88.0]
Duration of the illness, days 3.9 (3.6) 3.0 (1.6) 0.216
[1.0–8.0] [1.0–7.0]
Axillary temperature, °C 38.4(0.8) 38.7 (1.4) 0.125
[37.2–40.5] [ 37.1–41.1]
Systolic blood pressure, mm Hg 72.5 (23.4) 72.5 (13.8) 0.987
[0–130.0] [60.0–130.0]
Diastolic blood pressure, mm Hg 47.0 (17.7) 50.0 (10.1) 0.414
[0–100.0] [30.0–70.0]
Parasite count, rings/μl, Geometric 5,934.2 13,906.6 0.013
[1600–380000] [1500–115200]
Haemoglobin, gm/dl 10.4 (2.6) 9.8(3.0) 0.302
[3.6–14.2] [3.8–13.9]
White blood cells, cell/mm3 5,122.7 (1851) 5,507.7 (1,966) 0.346
[1,900.0–11,400] [1,800.0–9,000.0]
Blood glucose, mg/dl 110.7 (44.3) 106.8 (28.3) 0.670
[30.0–198.0] [30.–170.0]
Serum bilirubin, mg/dl 1.4 (1.0) 1.4 (1.2) 0.857
[0.2–5.6] [0.4–6.6]
Serum creatinine, mg/dl 0.9 (0.5) 0.9(0.3) 0.738
[0.1–4.6] [0.5–2.0]
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non-pregnant patients.
Interestingly, it has been observed that 36.2% of adult
patients in the same study area had anaemia regardless
of their age, sex, education level or infection with malaria
[12]. In Tanzania, the clinical manifestations of severe
malaria in children younger than five years were cerebral
malaria (47.3%) and severe anaemia (14.6%) [4]. Severe
anaemia (8.57%) and circulatory collapse (11.90%) wereTable 2 Comparison of clinical and biochemical characteristic
Variable Convulsion
(N = 18)
Age, years 39.5 (1.6)
Haemoglobin, gm/dl 11.3 (3.1)
Blood glucose, mg/dl 106.5 (29.5)
White blood cells, cell/mm3 5,650(1,804)
Geometric mean of asexual stage parasitaemia per μL 4,339.7 (60,43the most common manifestations of severe malaria in
neighbouring Ethiopia [13]. In Southeast Asia, which is
characterized by unstable malaria transmission, the
incidence of anaemia and convulsions decreased with
age, whereas the incidence of hyperparasitaemia, jaundice,
and renal insufficiency increased with age [14]. In India,
acute renal failure and jaundice were more common in
adults whereas children frequently developed severe
anaemia, while cerebral malaria occurred equally in adultss of three main groups with severe malaria
Cerebral malaria Hypotension P-value
(N = 23) (N = 38)
43.0 (1.7) 36.4 (1.5) <0.001
11.2 (2.1) 9.7 (2.2) 0.020
123.2(33.1) 115.9 (54.0) 0.485
5,991(2,137.8) 5,229.0 (2,078) 0.361
6) 7,986.7 (82,014) 5,831.9 (67,614) 0.986
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patients presented with hypoglycaemia. It was previously
shown that 20% and 16% of children with severe malaria
in Malawi and Kenya, respectively, had hypoglycaemia
before treatment [16,17]. Hypoglycaemia is one of the
defining features of severe malaria according to WHO
guidelines, and indicates a poor prognosis [2]. Furthermore,
it is a treatable cause of other features of severe malaria
e g, coma and convulsions, especially in severe childhood
illnesses [2]. Recent findings showed a significant difference
between blood glucose levels between children who died
and survivors [18].
The manifestations of severe malaria were not signifi-
cantly different between P. falciparum and P. vivax malaria
in this report. Previously, P. vivax was considered the
cause of tertian benign malaria that rarely led to a severe
form of the disease. However, increasing evidence has
shown an increased risk of mortality and morbidity owing
to P. vivax malaria [10,19-22]. Generally, most reports on
severe P. vivax malaria are from Southeast Asia and
India, and there have been few published data on
severe P. vivax from Africa. It has been documented
different manifestations of severe P. vivax malaria among
children in a nearby hospital (New Halfa) [10]. The
clinical presentation of severe malaria caused by P. vivax
in India presented with cerebral malaria, severe anaemia,
renal failure, hypoglycaemia, jaundice, acute respiratory
distress syndrome, shock, and death [20]. However, to the
best of the knowledge, there have been no reports from
African countries regarding adult patients with malaria.
Of note, there are no specific manifestations or treatment
for severe P. vivax malaria, but according to the
WHO guidelines, it should be considered as severe as
P. falciparum malaria [11].
In the current study, three patients (2.0%) died owing
to severe P. falciparum malaria. In Tanzania, the fatality
rate of severe malaria was 3.2% and the majority of
deaths occurred in children younger than five years [4].
High mortality rates (33.3%), mainly in young adults,
were observed among patients with severe malaria at
Dakar, Senegal [23]. Likewise, a high fatality rate (24.1%)
was observed among 1,050 patients with severe malaria
in Southeast Asia, where mortality increased from 6.1%
in children to 36.5% in patients aged >50 years [15]. Low
death rates may be caused by underestimation, as some
cases of severe malaria might have died at home without
access to hospital treatment. Furthermore, the low rate
of hypoglycaemia in this study could explain the low
mortality rate itself where recent study showed a significant
difference between blood glucose levels between children
who died and survivors [18]. It is also possible that genetic
factors might explain the mortality in this setting.
There are some limitations of this study; manifestations
of the disease itself were overlaps and might not be strictlyfollowed e.g. hypotension is only severe disease if not
responsive to fluids, bleeding by itself is not severity as
well, unless it is followed by circulatory collapse and
hyperbilirubinaemia is considered a severity criterion if
its followed by other organ dysfunctions. Furthermore
PCR was not performed in any sample of the patients to
confirm the parasite species as has been done in some
other setting [24].
Conclusions
Severe malaria due to P. falciparum or P. vivax malaria
is an entity that exists among adults in eastern Sudan,
with similar manifestations between severe P. falciparum
and P. vivax.
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